Stem Cell Therapy for Parkinson’s Disease (PD)

ANOVA IRM first reviews whether its MSEC approach may be appropriate before developing a treatment plan. International patients can complete this initial stage from home without making travel arrangements for Germany.

Submitting the contact form begins the process. ANOVA then sends information specific to Parkinson’s disease, explaining its MSEC approach, experimental status and the steps that may follow.

Patients who choose to move forward are told which materials to provide. These may include medical records confirming the Parkinson’s diagnosis, details about disease stage and symptoms, current medications and therapies, recent diagnostic findings and other relevant health information.

Once the necessary information is available, patient care can arrange a consultation with an ANOVA physician. The consultation helps determine whether in-person eligibility testing and treatment planning should be considered.

Following a consultation that indicates potential suitability, patients are generally advised to arrange preliminary blood tests in their home country before making the trip to Germany.

This initial screening is used to identify exclusions including HIV, hepatitis A, B or C, syphilis and other active infectious diseases. It also considers relevant medical or substance-use risk factors. Completing the tests locally can prevent travel when a known contraindication has already been identified.

If screening does not reveal an exclusion, the patient may plan a visit to ANOVA IRM in Offenbach. The required bloodwork is performed again on the first day to satisfy German medical requirements. The physician then completes the final assessment before the patient’s biological material enters MSEC production.

Adipose tissue collection by mini-liposuction is normally scheduled for the following day.

The treatment schedule is tailored to the individual. ANOVA uses standard protocol patterns as starting frameworks, taking account of the patient’s Parkinson’s stage and symptoms, physician findings, ability to return to Offenbach and other practical needs.

For Parkinson’s disease, the following three patterns may help guide scheduling:

• Boost + Balanced: The cycle opens with three doses during the first treatment visit. The remaining seven doses are delivered individually, usually at three-month intervals. This pattern is most feasible for patients with a high level of travel readiness.
• Balanced-Boost: The full 10-dose cycle is distributed across four visits, typically separated by six months. The longer interval can make this schedule more practical for international patients or those with limited travel availability.
• Intense Balanced-Boost: This protocol also distributes 10 doses across four visits but normally reduces the spacing between visits to three months. It may be considered when the physician determines that a more intensive schedule is appropriate.

These are general examples rather than the only available schedules. The physician may adjust the timing and distribution of doses according to the patient’s medical and practical requirements.

ANOVA IRM discusses the proposed dosing calendar, individualized cost and required trips before the patient proceeds. Any stored MSEC must be used within its two-year shelf life.

The initial visit to Offenbach generally requires approximately two consecutive days. Required bloodwork and final medical confirmation take place on the first day, with mini-liposuction normally scheduled for the following day.

After receiving physician clearance, the patient undergoes a limited mini-liposuction under light sedation to obtain abdominal adipose tissue.

The collected sample is used to isolate and cultivate mesenchymal stem cells, allowing their secretome to be produced. Only the secreted bioactive factors, rather than viable MSCs, remain in the treatment preparation.

The MSEC product is enriched and passes quality-control procedures before being frozen for storage. The first applications can usually be scheduled approximately four weeks after tissue collection.

Application appointments are scheduled at ANOVA IRM in Offenbach according to the individualized schedule developed during treatment planning.

Repeated dosing may form part of the plan because Parkinson’s disease is chronic and progressive. Where the physician considers it appropriate, appointment timing can account for the practical demands on patients travelling from more distant regions.

Every dose must be used before the stored MSEC reaches the end of its two-year shelf life. Continuing once the supply has expired or been fully used requires a new tissue collection and production cycle.

Yes. ANOVA IRM offers experimental autologous Mesenchymal Stem Cell Secretome therapy for selected patients with Parkinson’s disease. Treatment takes place in Offenbach, Germany, following an individual medical review.

No stem-cell-based treatment has been established as a cure for Parkinson’s disease. ANOVA’s MSEC is applied as an experimental treatment option alongside established Parkinson’s care, not as dopamine-producing cell-replacement therapy.

Research into MSC-derived extracellular vesicles has reported encouraging preclinical findings involving inflammatory, neuroprotective and repair-related pathways relevant to Parkinson’s disease. These findings provide a scientific rationale for investigating stem-cell-derived factors as a potential therapeutic approach.

Recent human trials involving transplanted dopamine-producing cells also demonstrate progress in regenerative Parkinson’s research. However, those trials evaluate a different intervention from ANOVA’s cell-free MSEC therapy, for which clinical evidence in Parkinson’s disease remains limited.

ANOVA IRM primarily considers selected patients with early-to-mid-stage Parkinson’s disease. Disease stage is only one part of eligibility, which also depends on symptoms, current treatment, medical history, overall health and an individual medical review.

No. MSEC is a cell-free treatment made from substances released by the patient’s own adipose-derived mesenchymal stem cells.

It differs from clinical trials in which dopamine-producing cells derived from pluripotent stem cells, including embryonic stem cells and induced pluripotent stem cells, are surgically transplanted into the brain to replace lost neurons. ANOVA does not perform this form of cell transplantation.

No. MSEC is reviewed alongside established Parkinson’s care, not as a replacement for it. Patients should continue medications, rehabilitation and other treatments as directed by their neurologist unless their treating physician recommends a change.

ANOVA administers MSEC systemically by infusion during scheduled visits in Offenbach. The physician determines how many doses are given during each visit and how the applications are distributed across the treatment period.

Stem-cell-based therapies encompass several different experimental approaches. Current clinical evidence is still developing, and further controlled trials are needed to establish the safety, efficacy and appropriate use of each approach.

Yes. International patients can begin with a remote inquiry, medical-information review and physician consultation. Patients who are approved to proceed should expect an initial trip for testing and tissue collection, followed by return visits for MSEC applications.

Parkinson’s disease develops as dopamine-producing nerve cells in an area of the brain called the substantia nigra become damaged and are gradually lost.

The underlying reason for this cell loss is not fully understood. Researchers believe that genetic susceptibility, environmental exposures and ageing may contribute, but most cases cannot be attributed to a single identifiable cause.

Early signs can be subtle and may initially affect only one side of the body. They can include a tremor at rest, slower movement, muscle stiffness, reduced arm swing, smaller handwriting, a softer voice or reduced facial expression.

Loss of smell, constipation and sleep disturbances may also occur before or alongside movement symptoms. No single symptom confirms Parkinson’s disease, and persistent changes should be assessed by a physician.

The main movement symptoms are tremor, slowed movement, muscle rigidity and changes in balance, posture or walking.

Parkinson’s can also cause non-motor symptoms such as fatigue, sleep problems, depression, anxiety, constipation, loss of smell, pain and changes in speech, swallowing, memory or thinking. The combination, severity and progression of symptoms vary considerably between patients.

Parkinson’s progression is commonly described using the five-stage Hoehn and Yahr scale:

• Stage 1: Mild movement symptoms affect one side of the body and have limited impact on daily activities.
• Stage 2: Symptoms affect both sides of the body, but balance is generally preserved. Daily tasks may take longer or become more difficult.
• Stage 3: Balance problems and falls may emerge, although the person can often continue living independently.
• Stage 4: Symptoms become severely limiting, and substantial assistance may be needed for everyday activities.
• Stage 5: Standing or walking may no longer be possible without assistance, and continuous care may be required.

This scale mainly describes motor disability. Parkinson’s does not progress at the same rate or in precisely the same sequence for every patient.

Many people live with Parkinson’s disease for years or decades, but average life expectancy is generally reduced compared with people without the condition. Individual outlook varies with age at diagnosis, overall health, disease progression and complications affecting mobility or swallowing.